In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors

The Journal of Clinical Investigation
A KojimaR G Crystal

Abstract

To evaluate the concept that in vivo transfer of the human carboxylesterase gene will confer sensitivity of a solid tumor to the prodrug CPT-11 (irinotecan), we constructed an adenovirus vector (AdCMV.CE) carrying the human carboxylesterase gene driven by the cytomegalovirus (CMV) promoter, infected A549 human lung adenocarcinoma cells in vitro and in vivo, and evaluated cell growth over time. AdCMV.CE produced a functional carboxylesterase protein in A549 cells in vitro and in vivo as evidenced by ability of lysates from the infected cells to convert CPT-11 to its active metabolite SN-38. The AdCMV.CE vector effectively suppressed A549 cell growth in vitro in the presence of CPT-11. Cell mixing studies demonstrated that when as few as 10% of cells expressed the human carboxylesterase gene, there was bystander growth suppression in the presence of CPT-11. Consistent with these in vitro observations, when AdCMV.CE was directly injected into established subcutaneous A549 tumors in nude mice receiving CPT-11, there was 35% reduction in tumor size at day 27 compared to controls, and a 41% reduction at day 34 (P < 0.01, both comparisons to controls). Similar observations were made with the cell line H157 and HeLa. These observations...Continue Reading

References

Jun 17, 1992·Journal of the National Cancer Institute·Y OheH Ohmatsu
Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MasudaM Takada
Jan 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·C A MullenR M Blaese
Sep 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·P S Thomas
Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·S H ChenS L Woo

❮ Previous
Next ❯

Citations

Jul 14, 2000·The Journal of Gene Medicine·M AghiX O Breakefield
Jul 25, 2009·Cancer Chemotherapy and Pharmacology·Hironori IwasakiHirosuke Oku
Jun 12, 1999·British Journal of Haematology·J E HumphriesT C Morris
Jun 7, 2005·Expert Opinion on Biological Therapy·Daniel H PalmerPhilip J Johnson
Feb 20, 2007·Molecular Aspects of Medicine·Daniel PortsmouthMatthias Renner
Sep 16, 2006·Biochimica Et Biophysica Acta·Daniel B LongleyPatrick G Johnston
Jul 6, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Claudia Rossig, Malcolm K Brenner
Dec 9, 2016·Human Gene Therapy·Dolan SondhiRonald G Crystal
Feb 29, 2008·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Masakiyo Hosokawa
Feb 9, 2008·Pharmacology·Howard R Mellor, Richard Callaghan
Aug 2, 2003·Nature Reviews. Cancer·David Kerr
Sep 19, 2002·British Journal of Cancer·D OosterhoffW R Gerritsen
Apr 21, 2009·Expert Review of Anticancer Therapy·Camilla L ChristensenHans S Poulsen
Oct 12, 2000·Medical and Pediatric Oncology·C Rodriguez-GalindoP J Houghton
Feb 24, 2001·Annals of the New York Academy of Sciences·L P Rivory
Nov 8, 2002·British Medical Bulletin·Daniel H PalmerDavid J Kerr

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.